A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Latest Information Update: 24 Jul 2026
At a glance
- Drugs Loncastuximab tesirine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions
- Acronyms LOTIS-10
- Sponsors ADC Therapeutics
Most Recent Events
- 20 Jul 2026 Status changed from recruiting to discontinued.
- 06 Nov 2023 Status changed from not yet recruiting to recruiting.
- 24 Jul 2023 Planned initiation date changed from 19 Dec 2022 to 14 Aug 2023.